Jeepers, you would think that cancer immunotherapy has all of a sudden been banned by the FDA.
The after market action for DNDN is due to sale forecasts and not because of the science behind Provenge.
After market trading tends to be extremely volatile on the U.S. markets. It should bounce back somewhat tomorrow. If it doesn't you would think that DNDN would be a takeover target.
The DNDN sales team need to get out on the road an educate.
It's a pity Obama and his medicare/medicaid issues are creating all this confusion for DNDN.
Provenge has full coverage. DNDN just need to get the word out there!
top up opportunity - technical counsel. , page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $1.817M | 5.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71665 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 36363 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |